Illimis Therapeutics
PrivateLast Round
Grant
Jul 15, 2025
Est. Valuation
$107.17M
Total Funding Raised
$60.01M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Illimis Therapeutics is a biotechnology company developing fusion protein-based therapeutics for the treatment of intractable diseases like Alzheimer's and other immune-related disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Illimis Therapeutics Comparables
Compare Illimis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pin Therapeutics | 91% | |
| UPPTHERA | 89% | |
| Cyrus Therapeutics | 89% |
Illimis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 15, 2025 | ||||
| Series B | Jul 14, 2025 | ||||
| Series A | Apr 14, 2023 | ||||
| Seed | Dec 1, 2021 |
Key People
Founding team and executive leadership
Illimis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hana Ventures | Series B |
| DSC Investment | Series B |
| A Ventures | Series B |
| Shinhan Venture Investment | Series B |
| DAYLI Partners | VC Round, Series B, Series A |
| TS Investment | Series B |
| GS Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 506% MoM to 10.1K.
- Jun 20, 2026
Monthly visitors increased 137% MoM.
Illimis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Illimis Therapeutics's valuation, stock price, and market status.
Is Illimis Therapeutics a public or private company?
Illimis Therapeutics is a private company.
What is the current stock price of Illimis Therapeutics?
Illimis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Illimis Therapeutics worth (valuation)?
Illimis Therapeutics's valuation is estimated at $107.2M based on funding round data.
Can I buy Illimis Therapeutics stock?
Illimis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Illimis Therapeutics's last funding round?
Illimis Therapeutics's most recent funding round was Grant on July 14, 2025.
Who are the main investors in Illimis Therapeutics?
Key investors in Illimis Therapeutics include DSC Investment, DAYLI Partners, Company K Partners, Woori Venture Partners Co., Ltd., Daol Investment.
Will Illimis Therapeutics IPO soon?
No public IPO plans have been announced for Illimis Therapeutics.
How can I track Illimis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Illimis Therapeutics's secondary market activity and sign up for updates.